# Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT04886206** · PHASE1 · UNKNOWN · sponsor: **Nantes University Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** DLI

## Key facts

- **NCT ID:** NCT04886206
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-10
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04886206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04886206, "Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04886206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*